Ripple Therapeutics宣布与艾伯维公司达成 合作和 许可
选择协议，共同开发下一代青光眼治疗方案

- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma

TORONTO, ON / ACCESSWIRE / September 17, 2024 / Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple's innovative drug delivery platform.

Ripple's patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly customizable to tailor both drug dose and duration. Because there are no polymers or excipients, once the drug is gone, the implant is gone with no pro-inflammatory degradation products, which supports repeat dosing.

"We're pleased to partner with AbbVie, a worldwide leader in ophthalmic therapeutics," said Tom Reeves, President and Chief Executive Officer, Ripple Therapeutics. "By combining our drug delivery platform with AbbVie's research, clinical, regulatory and commercial capabilities, we hope to deliver a meaningful impact on the lives of people living with glaucoma."

Millions of people are living with glaucoma, one of the leading causes of vision loss. New treatment options are needed to help patients challenged with topical drops or who are at risk for vision loss and looking for alternative treatment options.

"At AbbVie, we strive to find innovative solutions to build our portfolio of vision-preserving therapies," said Michael Robinson, M.D., Vice President and Therapeutic Area Head, Ophthalmology, AbbVie. "We are excited to partner with Ripple to further advance the development of RTC-620."

Under terms of the agreement, Ripple will lead preclinical development of RTC-620. Upon exercise of the option, AbbVie will lead the clinical and commercialization activities. Ripple will receive an upfront payment of $21.8 million from AbbVie and is eligible to receive up to $290 million in aggregate option fees and milestoneRipple Therapeutics宣布与艾伯维公司达成合作和许可选择协议，共同开发下一代青光眼治疗方案s, as well as tiered royalties on net sales.

About Ripple Therapeutics

Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants without the use of polymers or exciRipple Therapeutics宣布与艾伯维公司达成合作和许可选择协议，共同开发下一代青光眼治疗方案pients. Our novel therapeutics provide better outcomes for patients, easier management of care for physicians and lower cost for payors.

Piper Sandler acted as the exclusive financial advisor to Ripple.

For further information:

Media: Julie Fotheringham, jfotheringham@rippletherapeutics.com, 416-951-7988

SOURCE: Ripple Therapeutics

未经允许不得转载：東君御酒 中华神酒 天下第一酒 酒中的劳斯莱斯,喝東君酒60变30 极品原料、天人合一、内外皆养、极致品位、色香味力、旷世享受、珍奇百草酿美酒、天地造化四海扬、盖世秘传历千秋、神奇美酒東君王 Ripple Therapeutics宣布与艾伯维公司达成合作和许可选择协议，共同开发下一代青光眼治疗方案